The Technical Analyst
Baudax Bio Inc [BXRX]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Baudax Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
3.66% $3.40
America/New_York / 3 feb 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.887 mill |
| EPS: | 350.33 |
| P/E: | 0.0100 |
| Earnings Date: | Mar 14, 2023 |
| SharesOutstanding: | 0.555 mill |
| Avg Daily Volume: | 2.16 mill |
| RATING 2023-02-03 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0.0100 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE 0.0100 | industry: PE 12.65 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1 839 047 (54 089 506.29%) $1 839 043 |
| Date: 2023-02-05 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.66 - 4.14 ( +/- 21.82%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-12-15 | Henwood Geraldine | Buy | 1 200 | Common Stock |
| 2022-06-15 | Weisman Wayne | Buy | 39 473 | Common Stock |
| 2022-06-15 | Henwood Geraldine | Buy | 39 473 | Common Stock |
| 2022-06-15 | Dilmore Jillian | Buy | 15 467 | Common Stock |
| 2022-06-15 | Drechsler Andrew T | Buy | 39 473 | Common Stock |
| INSIDER POWER |
|---|
| 89.97 |
| Last 77 transactions |
| Buy: 13 000 393 | Sell: 9 375 394 |
Forecast:
16:00 - $3.38
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.38
Forecast 2: 16:00 - $3.38
Forecast 3: 16:00 - $3.38
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.40 (3.66% ) |
| Volume | 0.925 mill |
| Avg. Vol. | 2.16 mill |
| % of Avg. Vol | 42.79 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BXRX
77 Signals | Accuracy: 20.78% | Accuracy Buy: 30.77% | Accuracy Sell: 10.53%
Avg return buy: -0.26 % | Avg return sell: 0.65 %
$1 invested is now $0.89 or -10.89% since 03-01-23
| Date | Signal | @ | Closed | % | Jan 18 - 10:14 | sell | $3.46 | N/A | Active |
|---|---|---|---|---|
| Jan 17 - 16:00 | buy | $3.49 | $3.46 @ Jan 18 - 10:14 | -0.86% |
| Jan 17 - 15:27 | sell | $3.45 | $3.49 @ Jan 17 - 16:00 | 1.16% |
| Jan 17 - 15:23 | buy | $3.47 | $3.45 @ Jan 17 - 15:27 | -0.58% |
| Jan 17 - 15:05 | sell | $3.45 | $3.47 @ Jan 17 - 15:23 | 0.58% |
| Jan 17 - 13:15 | buy | $3.46 | $3.45 @ Jan 17 - 15:05 | -0.29% |
| Jan 17 - 13:14 | sell | $3.45 | $3.46 @ Jan 17 - 13:15 | 0.29% |
| Jan 17 - 13:09 | buy | $3.35 | $3.45 @ Jan 17 - 13:14 | 3.04% |
| Jan 17 - 10:04 | sell | $3.30 | $3.35 @ Jan 17 - 13:09 | 1.46% |
| Jan 17 - 09:52 | buy | $3.36 | $3.30 @ Jan 17 - 10:04 | -1.79% |
BXRX
Latest Press Releases
2023-01-24 08:00:00 - Press Release
Baudax Bio Announces Positive Outcome Of Interim Analysis Of Phase Ii Randomized Trial For Bx1000
Malvern, pa., jan. 24, 2023 (globe newswire) -- baudax bio, inc. (nasdaq:bxrx) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful outcome of its first interim analysis in a phase ii trial of bx1000 for neuromuscular blockade (nmb) in patients undergoing elective surgery.
2022-12-08 08:00:00 - Press Release
Baudax Bio Initiates Phase Ii Clinical Trial Evaluating Bx1000 In Patients Undergoing Surgery
Malvern, pa., dec. 08, 2022 (globe newswire) -- baudax bio, inc. (nasdaq:bxrx) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the initiation of a clinical study evaluating the safety, tolerability profile, and intubation conditions of bx1000 for neuromuscular blockade (nmb) in patients undergoing elective surgery.
2022-12-06 16:11:00 - Press Release
Baudax Bio Announces Closing Of $5 Million Public Offering
Malvern, pa., dec. 06, 2022 (globe newswire) -- baudax bio, inc. (the “company” or “baudax bio”) (nasdaq: bxrx), a pharmaceutical company focused on innovative products for hospital and related settings, today announced the closing of its previously announced public offering of an aggregate of 1,042,787 shares of its common stock (or pre-funded warrants in lieu thereof), series a-3 warrants to purchase up to 1,042,787 shares of common stock and series a-4 warrants to purchase 1,042,787 shares of common stock, at a combined public offering price of $4.795 per share (or pre-funded warrant) and accompanying warrants. the series a-3 warrants have an exercise price of $4.50 per share, are exercisable immediately upon issuance and will expire five years from the date of issuance, and the series a-4 warrants have an exercise price of $4...
2022-12-02 14:46:00 - Press Release
Baudax Bio Announces Pricing Of $5 Million Public Offering
Malvern, penn., dec. 02, 2022 (globe newswire) -- baudax bio, inc. (the “company” or “baudax bio”) (nasdaq: bxrx), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of a public offering of an aggregate of 1,042,787 shares of its common stock (or pre-funded warrants in lieu thereof), series a-3 warrants to purchase up to 1,042,787 shares of common stock and series a-4 warrants to purchase 1,042,787 shares of common stock, at a combined public offering price of $4.795 per share (or pre-funded warrant) and accompanying warrants. the series a-3 warrants will have an exercise price of $4.50 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance, and the series a-4 warrants will have an exercise price of $4...
2022-11-30 16:50:00 - Press Release
Baudax Bio Announces 1-for-40 Reverse Stock Split
Malvern, pa., nov. 30, 2022 (globe newswire) -- baudax bio, inc. (nasdaq:bxrx) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the company's board of directors has approved a 1-for-40 reverse stock split of its common shares (the “reverse stock split”). the reverse stock split will become effective at 12:01 a.m. eastern time on december 1, 2022 and the company's common stock will open for trading on the nasdaq capital market on a post-split basis under the company's existing trading symbol “bxrx”. at such time, the company's common stock will also commence trading under a new cusip number, 07160f404.
Latest News
2023-01-26 04:01:33 - MarketBeat
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. While the interim positive outcome is based on a 20-patient group, it expects to complete the phase 2 trial with 80 patients by the end of the first quarter of 2023.
2023-01-24 10:58:45 - InvestorPlace
Why Is Baudax Bio (BXRX) Stock Up 50% Today?
What caused Baudax Bio (NASDAQ: BXRX ) stock to double earlier today? The catalyst was undoubtedly this morning's announcement concerning a Phase 2 clinical trial of Baudax Bio's novel product, BX1000.
2022-12-30 06:00:00 - PennyStocks
Penny Stocks Risk Management: 3 Tips and Tricks
Use these penny stocks risk management tips for trading The post Penny Stocks Risk Management: 3 Tips and Tricks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-12-24 16:27:01 - InvestorPlace
The 7 Most Sold-Off Stocks of 2022
With a contentious time in 2022 coming to a close, it may be helpful to look back and consider the most sold-off stocks last year. Similar to learning from prior mistakes, investors may be able to garner lessons from the worst-hit market ideas.
2022-12-09 09:48:19 - InvestorPlace
Why Is Baudax Bio (BXRX) Stock Up 46% Today?
Baudax Bio (NASDAQ: BXRX ) stock is rocketing higher on Friday after the pharmaceutical company initiated a Phase 2 clinical trial of BX1000. BX1000 is the company's drug candidate for neuromuscular blockade in patients undergoing elective surgery.
2022-11-08 18:48:33 - Zacks Investment Research
Baudax Bio, Inc. (BXRX) Reports Q3 Loss, Lags Revenue Estimates
Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of -366.04% and 75.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-10-24 09:02:11 - Zacks Investment Research
New Strong Buy Stocks for October 24th
BXRX, WOLF, GHRS, RKDA and BHR have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2022.
2022-09-08 16:05:00 - GlobeNewsWire
Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference
MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 24th Annual H.C. Wainwright Healthcare Conference, taking place in New York, New York on Wednesday, September 14, 2022 at 3:00 p.m. Eastern Time.
2022-09-02 20:22:13 - 24/7 Wall Street
These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)
Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).
2022-09-01 06:00:00 - PennyStocks
Most Active Penny Stocks to Buy Now? Check These 3 Out
Are penny stocks worth buying in September? The post Most Active Penny Stocks to Buy Now?